David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC

1:02:45
 
Share
 

Manage episode 315309945 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

324 episodes